Thyroid Carcinoma

Thyroid carcinoma is a malignant neoplasm arising from the follicular epithelial cells of the thyroid gland. In veterinary medicine, it is most commonly diagnosed in dogs, where it accounts for the majority of clinically significant thyroid tumors, whereas in cats, thyroid tumors are predominantly benign adenomas (functional adenomatous hyperplasia). Thyroid carcinomas are typically unilateral, firm, and invasive, often extending into adjacent cervical structures such as the trachea, esophagus, carotid sheath, and regional lymph nodes. They may be functional, producing excessive thyroid hormone and causing hyperthyroidism, or non-functional, leading to local signs without endocrine manifestations. Histologically, they are classified as follicular, compact, papillary, or mixed, with a high propensity for local invasion and distant metastasis, particularly to the lungs and regional lymph nodes. The clinical presentation varies from an asymptomatic cervical mass to severe systemic illness depending on hormonal status and metastatic burden.

The exact etiology of thyroid carcinoma in dogs and cats is largely unknown, but several factors have been implicated. Chronic stimulation of thyroid follicular cells by thyroid-stimulating hormone (TSH) is a proposed mechanism, as prolonged TSH hypersecretion may lead to follicular cell hyperplasia and eventually neoplasia. In dogs, there is no strong breed predisposition, but certain breeds such as Beagles, Boxers, and Golden Retrievers may be overrepresented. Genetic mutations, including activation of oncogenes (e.g., RAS, BRAF) and inactivation of tumor suppressor genes (e.g., p53), have been identified in human thyroid cancer and are suspected in veterinary cases. Environmental factors, such as exposure to radiation or goitrogenic substances, may contribute, though evidence is limited. In cats, the vast majority of thyroid tumors are benign adenomas, and malignant carcinomas are rare, with no clear etiological agent identified. Chronic inflammation (thyroiditis) has been hypothesized as a precursor, but definitive evidence is lacking.

Thyroid carcinoma is primarily a disease of middle-aged to older dogs, with a median age of 9 to 10 years. No significant sex predilection is consistently reported, though some studies suggest a slight female predominance. Certain breeds, including Beagles, Boxers, and Golden Retrievers, may be at higher risk. The incidence is relatively low, accounting for approximately 1-2% of all canine neoplasms, but it is the most common endocrine tumor in dogs. In cats, thyroid carcinoma is exceedingly rare, with benign adenomas comprising over 95% of feline thyroid tumors. When carcinomas do occur in cats, they are often seen in older animals, with no breed or sex predilection. Geographic variation is not well-documented, but iodine deficiency or excess may influence thyroid pathology. No clear seasonal pattern exists.

Thyroid carcinoma arises from follicular cells and disrupts normal thyroid hormone synthesis and regulation. Malignant transformation leads to uncontrolled cellular proliferation, invasion of surrounding tissues, and potential metastasis. The tumor may be functional, secreting excessive thyroxine (T4) and triiodothyronine (T3), resulting in hyperthyroidism, or non-functional, causing local compressive signs. In dogs, approximately 10-20% of thyroid carcinomas are functional, whereas in cats, most thyroid tumors are functional adenomas, but carcinomas are often non-functional. The invasive nature of the tumor can cause tracheal compression, dysphagia, dysphonia, and Horner's syndrome due to sympathetic trunk involvement. Metastasis occurs via hematogenous and lymphatic routes, most commonly to the lungs and regional lymph nodes. The tumor's growth and invasion lead to local tissue destruction, hemorrhage, and necrosis, contributing to clinical signs. Paraneoplastic syndromes, such as hypercalcemia, have been reported but are rare.

Intrinsic risk factors include advanced age, as thyroid carcinoma is more common in older dogs. Genetic predisposition may play a role, as certain breeds are overrepresented. Hormonal factors, such as chronic TSH stimulation, may promote tumorigenesis. Extrinsic factors include exposure to radiation, which is a known risk factor for thyroid cancer in humans and may be relevant in animals. Dietary factors, such as iodine deficiency or excess, could influence thyroid health. Concurrent diseases, such as chronic lymphocytic thyroiditis, may increase the risk. Immunosuppression, whether due to disease or medication, could potentially allow neoplastic progression. However, in most cases, no specific predisposing factor is identified.

Clinical signs of thyroid carcinoma depend on tumor size, invasiveness, and functional status. In dogs, the most common presentation is a palpable, firm, non-painful cervical mass in the ventral neck region. If the tumor is functional, signs of hyperthyroidism may be present, including weight loss, polyphagia, polydipsia, polyuria, tachycardia, hyperactivity, and heat intolerance. Non-functional tumors may cause local compressive signs such as dysphagia, dyspnea, coughing, voice change, and facial edema due to venous compression. Invasion of the recurrent laryngeal nerve can lead to laryngeal paralysis and voice change. Horner's syndrome (miosis, ptosis, enophthalmos, third eyelid protrusion) may occur if the sympathetic trunk is involved. In advanced cases, metastasis to the lungs may cause respiratory signs, and lymph node metastasis may be palpable. In cats, thyroid carcinoma is rare, but when present, it may present similarly with a cervical mass and signs of hyperthyroidism or local invasion.

Differential diagnoses for a cervical mass in dogs and cats include: 1) Thyroid adenoma (benign, usually functional in cats, non-functional in dogs), 2) Salivary gland neoplasia or sialocele, 3) Lymphadenopathy (reactive or neoplastic, e.g., lymphoma), 4) Carotid body tumor (chemodectoma), 5) Branchial cleft cyst, 6) Abscess or granuloma, 7) Foreign body reaction, 8) Other soft tissue sarcomas (e.g., fibrosarcoma, liposarcoma), 9) Metastatic neoplasia from other sites. Definitive differentiation requires diagnostic imaging (ultrasound, CT), fine-needle aspiration cytology, and histopathology. Thyroid scintigraphy can help identify functional thyroid tissue, which is characteristic of thyroid tumors.

The diagnostic approach to a suspected thyroid carcinoma begins with a thorough history and physical examination, focusing on the cervical mass and signs of hyperthyroidism. Baseline laboratory tests, including complete blood count, serum biochemistry, and urinalysis, are recommended to assess overall health and detect paraneoplastic syndromes. Serum thyroid hormone levels (total T4, free T4, TSH) should be measured to determine functional status. Cervical radiographs may reveal a soft tissue mass, tracheal deviation, or mineralization. Thoracic radiographs are essential to evaluate for pulmonary metastasis. Ultrasonography of the thyroid gland can characterize the mass (echogenicity, vascularity, invasion) and guide fine-needle aspiration. Computed tomography (CT) or magnetic resonance imaging (MRI) provides detailed anatomical information, especially for surgical planning and assessment of local invasion. Thyroid scintigraphy (using technetium-99m pertechnetate) can confirm thyroid origin and detect ectopic thyroid tissue or metastasis. Definitive diagnosis requires histopathology, obtained via surgical biopsy or post-surgical examination. Fine-needle aspiration cytology can be supportive but may not differentiate benign from malignant lesions reliably.

Hematology: Complete blood count may be normal, but in cases of hyperthyroidism, mild erythrocytosis or stress leukogram may be present. Serum biochemistry: In hyperthyroid animals, liver enzymes (ALT, ALP) may be elevated due to increased metabolism. Hypercalcemia may occur as a paraneoplastic syndrome. Thyroid hormone assays: Total T4 and free T4 are elevated in functional tumors, while TSH is typically suppressed. In non-functional tumors, thyroid hormone levels are usually within normal limits. Thyroglobulin autoantibodies may be present in some cases. Urinalysis: Generally unremarkable, but may show low urine specific gravity if hyperthyroidism causes polyuria. Blood gas analysis: Not typically indicated unless respiratory compromise is present. Specific biomarkers: Thyroglobulin levels may be elevated in thyroid carcinoma, but its utility is limited. Serum calcium and phosphorus should be monitored. In cases of metastasis, lactate dehydrogenase (LDH) may be elevated.

Radiography: Cervical radiographs may show a soft tissue mass in the ventral neck, with possible tracheal deviation or compression. Thoracic radiographs are crucial to detect pulmonary metastasis, which appears as multiple nodular interstitial patterns. Ultrasonography: Thyroid ultrasound reveals a hypoechoic, heterogeneous mass with irregular margins, often with increased vascularity on Doppler. Invasion into adjacent structures may be visible. Computed Tomography (CT): CT provides excellent detail of the mass, its extent, and invasion into surrounding tissues, including the trachea, esophagus, and vasculature. It is essential for surgical planning and staging. Magnetic Resonance Imaging (MRI): MRI offers superior soft tissue contrast and is useful for evaluating invasion into the spinal canal or mediastinum. Thyroid Scintigraphy: Using technetium-99m pertechnetate, thyroid scintigraphy shows increased uptake in functional thyroid tumors, and can identify ectopic thyroid tissue and metastatic lesions. This is particularly useful in cats to differentiate adenomas from carcinomas.

Fine-needle aspiration cytology of thyroid masses often yields highly cellular smears with clusters of follicular cells. Cytological features may include anisocytosis, anisokaryosis, prominent nucleoli, and high nuclear-to-cytoplasmic ratio, but these features are not always reliable to distinguish adenoma from carcinoma. Histopathology is the gold standard for diagnosis. On histology, thyroid carcinomas show capsular invasion, vascular invasion, and cellular atypia. They may be classified as follicular, compact, papillary, or mixed. Immunohistochemistry for thyroglobulin and thyroid transcription factor-1 (TTF-1) can confirm thyroid origin. Metastasis to regional lymph nodes or lungs is a definitive criterion for malignancy.

Treatment of thyroid carcinoma depends on tumor resectability, presence of metastasis, and functional status. Surgical excision is the treatment of choice for non-invasive, movable tumors. Complete thyroidectomy (unilateral or bilateral) may be curative if complete excision is achieved. However, invasive tumors may be difficult to resect completely, and surgery may be associated with complications such as hypoparathyroidism, laryngeal paralysis, and hemorrhage. For non-resectable or metastatic tumors, radiation therapy (external beam radiotherapy) is highly effective and can provide long-term control. Radioactive iodine (I-131) therapy is an option for functional tumors, especially in cats, but is less commonly used in dogs due to cost and availability. Chemotherapy (e.g., doxorubicin, cisplatin) has limited efficacy but may be considered for metastatic disease. Medical management of hyperthyroidism (e.g., methimazole) may be used to control clinical signs before definitive treatment. Supportive care includes nutritional support, pain management, and management of complications such as hypocalcemia after surgery.

The prognosis for thyroid carcinoma in dogs is variable and depends on tumor size, invasiveness, and presence of metastasis. Dogs with small, movable tumors that are completely excised have a good prognosis, with median survival times exceeding 3 years. In contrast, dogs with invasive or metastatic tumors have a poorer prognosis, with median survival times of 6-12 months. Radiation therapy can improve outcomes for non-resectable tumors, with median survival times of 2-3 years. In cats, thyroid carcinoma is rare but carries a guarded prognosis due to high metastatic potential. Negative prognostic factors include large tumor size (>5 cm), invasion into surrounding tissues, lymph node or distant metastasis, and non-functional tumors. Response to treatment, particularly surgical excision, is a positive prognostic indicator.

Post-treatment monitoring is essential. After surgical excision, recheck examinations should be performed at 1, 3, and 6 months, then every 6-12 months. Serial thoracic radiographs or CT scans are recommended to monitor for pulmonary metastasis. Thyroid hormone levels should be assessed periodically, especially if the tumor was functional, to ensure euthyroidism. If radiation therapy is used, follow-up imaging is needed to assess tumor response and detect recurrence. For dogs with hypothyroidism after bilateral thyroidectomy, lifelong thyroid hormone supplementation (levothyroxine) is required, with monitoring of T4 levels. Serum calcium should be monitored for hypocalcemia due to parathyroid gland damage. Owners should be educated on signs of recurrence or metastasis.

Pearls: 1) Always perform thoracic radiographs or CT in any dog with a thyroid mass to rule out pulmonary metastasis. 2) Thyroid scintigraphy is invaluable for confirming thyroid origin and detecting ectopic thyroid tissue. 3) Invasive thyroid tumors may still be amenable to radiation therapy, which can provide excellent long-term control. 4) Preoperative measurement of ionized calcium is important to assess parathyroid function. Pitfalls: 1) Fine-needle aspiration cytology cannot reliably differentiate benign from malignant thyroid tumors; histopathology is required. 2) Avoid surgical biopsy of a thyroid mass without prior imaging, as it may cause hemorrhage and complicate subsequent surgery. 3) Do not assume a cervical mass is a thyroid tumor; other differentials must be considered. 4) In cats, most thyroid masses are benign adenomas, but carcinomas can occur; do not overlook malignancy in cats with atypical features.

For hyperthyroidism secondary to functional thyroid carcinoma, methimazole (Tapazole) is used at a dose of 5 mg per cat orally every 12 hours, or 10-15 mg per dog orally every 12 hours, adjusted based on T4 levels. For long-term management, radioactive iodine (I-131) is the treatment of choice for functional tumors, but it requires specialized facilities. For non-resectable tumors, radiation therapy (external beam) is recommended, typically administered in fractionated doses (e.g., 48-54 Gy total in 16-18 fractions). Chemotherapy with doxorubicin (30 mg/m² IV every 3 weeks) or cisplatin (60 mg/m² IV every 3 weeks) may be considered for metastatic disease, but response rates are low. For pain management, non-steroidal anti-inflammatory drugs (e.g., carprofen 2.2 mg/kg PO q12h) or opioids (e.g., tramadol 2-5 mg/kg PO q8-12h) may be used. Post-surgical hypocalcemia is managed with calcium gluconate (10% solution, 0.5-1.5 ml/kg IV slowly) and calcitriol (2.5-6.5 ng/kg/day PO). Hypothyroidism is treated with levothyroxine (0.02 mg/kg PO q12h in dogs, 0.05-0.1 mg per cat PO q12h), with dose adjustments based on T4 levels.

Several studies have evaluated the outcomes of thyroid carcinoma in dogs. A retrospective study by Klein et al. (1995) reported that dogs with movable thyroid tumors treated with surgery had a median survival of 36 months, while those with fixed tumors had a median survival of 6 months. Another study by Theon et al. (2000) demonstrated that radiation therapy for non-resectable thyroid tumors resulted in a median survival of 24 months, with good local control. A study by Barber (2007) highlighted the importance of staging with CT and scintigraphy. In cats, thyroid carcinoma is rare, but a case series by Naan et al. (2006) reported a high metastatic rate and poor prognosis. Consensus guidelines from the Veterinary Society of Surgical Oncology (VSSO) recommend surgical excision for resectable tumors and radiation therapy for invasive tumors. Chemotherapy is not well-supported by evidence. Overall, the literature emphasizes the importance of early detection and aggressive local therapy for improved outcomes.